Figure 6
From: Defining cutaneous molecular pathobiology of arsenicals using phenylarsine oxide as a prototype
PAO activates PERK/ATF4 and XBP-1 branch of UPR signaling in human keratinocytes.
(A,B) Western blot analysis showing dose- and time -dependent increase in UPR signaling pathway proteins GRP78, p-eIF2α, ATF4 and CHOP following PAO treatment in HaCaT cells. (C) Real time PCR analysis of PAO-induced GRP78 and CHOP mRNA expression in HaCaT cells. (D) Immunofluorescence staining of PAO-induced GRP78 in HaCaT cells. (E) Semi-quantitative PCR analysis of spliced XBP-1 (sXBP-1) in PAO-treated and vehicle-treated HaCaT cells. (F) Western blot analysis of spliced ATF6α (50 kDa) in PAO-treated and vehicle-treated HaCaT cells. Data are expressed as mean ± SEM. ***P < 0.001 show significance levels.
